Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Sinphar Pharmaceutical Co stock

1734.TW
TW0001734002

Price

30.65
Today +/-
+0.00
Today %
+0.16 %
P

Sinphar Pharmaceutical Co stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Sinphar Pharmaceutical Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Sinphar Pharmaceutical Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Sinphar Pharmaceutical Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Sinphar Pharmaceutical Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Sinphar Pharmaceutical Co Stock Price History

DateSinphar Pharmaceutical Co Price
11/7/202430.65 undefined
11/6/202430.60 undefined
11/5/202430.65 undefined
11/4/202430.65 undefined
11/1/202430.80 undefined
10/30/202430.80 undefined
10/29/202430.80 undefined
10/28/202431.00 undefined
10/25/202431.00 undefined
10/24/202431.25 undefined
10/23/202431.15 undefined
10/22/202431.20 undefined
10/21/202431.25 undefined
10/18/202430.80 undefined
10/17/202430.90 undefined
10/16/202430.80 undefined
10/15/202431.05 undefined
10/14/202431.60 undefined
10/11/202431.75 undefined

Sinphar Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Sinphar Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Sinphar Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Sinphar Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Sinphar Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Sinphar Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Sinphar Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Sinphar Pharmaceutical Co’s growth potential.

Sinphar Pharmaceutical Co Revenue, EBIT and net profit per share

DateSinphar Pharmaceutical Co RevenueSinphar Pharmaceutical Co EBITSinphar Pharmaceutical Co Net Income
20232.96 B undefined286.06 M undefined375.17 M undefined
20222.86 B undefined197.34 M undefined224.64 M undefined
20212.43 B undefined-182.8 M undefined-38.1 M undefined
20202.39 B undefined-122.2 M undefined-28.5 M undefined
20192.39 B undefined-147 M undefined14 M undefined
20182.22 B undefined-119.3 M undefined8.8 M undefined
20172.13 B undefined-63 M undefined36.7 M undefined
20162.13 B undefined-142.2 M undefined16.5 M undefined
20152.19 B undefined-128.2 M undefined14 M undefined
20142.64 B undefined144.3 M undefined163.4 M undefined
20132.58 B undefined162.5 M undefined300.7 M undefined
20122.09 B undefined126.2 M undefined124.4 M undefined
20111.84 B undefined62.6 M undefined72.2 M undefined
20101.82 B undefined97.3 M undefined110.9 M undefined
20091.81 B undefined134.9 M undefined131 M undefined
20081.81 B undefined63.1 M undefined46.2 M undefined
20071.76 B undefined86.1 M undefined80.6 M undefined
20061.64 B undefined41.1 M undefined43.9 M undefined
20051.71 B undefined137 M undefined155.8 M undefined
20041.41 B undefined131.9 M undefined121.9 M undefined

Sinphar Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.981.111.411.711.641.761.811.811.821.842.092.582.642.192.132.132.222.392.392.432.862.96
-13.2526.8221.65-4.437.692.610.170.500.9913.3723.542.52-17.22-2.470.053.808.08-0.251.8817.393.71
44.1444.0145.0045.2242.3139.5137.3539.8838.0937.6637.0637.4140.9935.9436.9937.9637.2539.2636.6436.5038.2036.83
0.430.490.630.780.690.70.680.720.690.690.770.961.080.790.790.810.830.940.880.891.091.09
62871311374186631349762126162144-128-142-63-119-147-122-182197286
6.327.839.307.992.504.883.487.395.323.376.046.295.45-5.85-6.66-2.95-5.37-6.14-5.11-7.486.909.66
627012115543804613111072124300163141636814-28-38224375
-12.9072.8628.10-72.2686.05-42.50184.78-16.03-34.5572.22141.94-45.67-91.4114.29125.00-77.7875.00-300.0035.71-689.4767.41
----------------------
----------------------
99.999.9110.6116.1125.3125.3133.4145146.3149.1167.7167.7167.7167.7167.7167.7167.8167.8167.7167.7168.01168.03
----------------------
Details

Keystats

Revenue and Growth

The Sinphar Pharmaceutical Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Sinphar Pharmaceutical Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                           
0.150.30.310.530.270.310.450.470.440.980.60.891.331.021.141.160.980.891.191.241.241.08
232.3246.1303.6355.8352.3374.6361.1322.9296.8289.9337.6382.9377.9396.9403.1370.4436.2486.9352.1433.7506.05477.25
104.4125.1125.4165.3127.2102.488.286.391106.8114.1125166.3152.4155156.2136148.4117.3159.3179.14166.21
240.5233.2274.7294.6366.5388.9378.9400.5420.2440.6518.4734.6861.9697.6611.6522.4488.1567681.4697.4737.01839.19
45.749.651.449.257.157.169.654.955.440.95697.152.350.153.145.486.4173.6194.6168.1112.0384.8
0.780.951.061.391.171.231.351.341.31.861.632.232.792.322.362.262.122.262.542.72.782.65
0.70.951.031.21.411.741.932.032.182.552.753.213.33.393.363.343.383.353.323.253.23.28
22.425.332.911.48.36.51.40018.24.686.6110.2238.390.4102.758.930.427.820.424.722.21
6.9000000000046.60000000031.430
25.225.178.972.9100.989.2109.27973.345.439.540185.7334.9304260.6217.9190.4157.5117.386.9871.82
66.552.94647.4000000000000000000
56.86292.5118.787.1100.5199.4135.1156.1131112.191.184.598.188.281.795.581.980.8133.190.68230.71
0.881.111.281.451.611.942.242.252.412.742.913.473.684.073.843.783.763.653.593.523.443.6
1.662.062.352.842.773.163.593.583.714.64.545.76.466.396.216.045.885.926.136.226.226.25
                                           
0.640.680.820.981.061.061.071.181.281.491.491.491.611.611.681.681.681.681.681.681.681.68
0.110.130.190.270.270.270.320.450.480.710.720.961.21.21.161.131.050.960.940.960.930.92
114.5131.6183.2240.3150.7175.4149.2242.6244.6270.2332.5551.2471.4352.6284.4295.2279.8275.8244.8210.7444.41634.15
2.89.1-2.710.623.236.566.277.625.80-14.65.927.64.3-49.6-57.8-63.3-98-86.3-91.9-80.7-92.72
00000000000-3.7-7.249.522.728.7-13.6-30.9-32.7-37.3-40.67-44.45
0.880.941.191.51.51.541.611.952.032.482.533.013.33.223.093.072.932.782.742.722.933.1
115.5105.5171173.3215.9170.5208.2205.7161.6166.8201.7291223.1207.2186157183.1211.7195201.4323.74291.37
53.556.187.3100.5103.7125.7130.2144.1166.90000000000000
47.157.771.942.255.168.6111.1117.4110287.4274.3462.6532.8412.3360.5350.7369.1416.9490.5684.8624.83462.61
305.7420.8487.9612.3485.9500.5638180157.8255214.6414.8332326312262255446552587447400
29161.119.521.121.534.432.4109.833.5388.343.751.146.176.87581.682.181.292.561.350.3450.72
0.550.80.840.950.880.91.120.760.631.10.731.221.131.020.930.850.891.161.331.531.451.2
0.180.160.160.20.190.510.640.660.840.730.950.811.041.051.211.321.381.411.511.491.421.49
0000000000000000000038.150
27.833.534.443.142.952.85772.386.8152.5159.3184.4212350.4278.5245.3184.4148.6143123.3106.81154.37
0.210.20.190.250.230.570.70.730.920.881.110.991.251.41.491.571.571.561.651.611.561.65
0.7611.031.191.111.461.821.491.551.981.852.212.392.432.422.422.462.712.983.143.012.85
1.641.942.222.72.6133.433.443.584.454.385.225.695.655.525.495.385.55.735.875.945.95
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Sinphar Pharmaceutical Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Sinphar Pharmaceutical Co's financial health and stability.

Assets

Sinphar Pharmaceutical Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Sinphar Pharmaceutical Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Sinphar Pharmaceutical Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Sinphar Pharmaceutical Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200220032004200520062007200820092010201120122013201420152016201720182019202020212022
627012115543804611210263148410207-58-34-52-87-86-117-184245
4854778699107119131145162163168193227259239238236250269266
-10-13-112-130-1240900000000000
-706-12-11918-237470-6-28-172-109-26099-669-78-248-525-109
-21-5-103171143-9201826-171813-7124618182523
212018111719292113141618202020192023262427
10121725417211824201668925039213941704447
91131741381661742713092612251642971482808721979-79146135425
-205-260-208-206-252-415-244-219-292-361-375-598-294-412-224-171-255-176-157-161-153
-197-146-256-259-255-444-393-187-309-405-372-617-273-480-13-226-179-210-165-205-124
8114-47-53-3-28-14932-17-433-1921-68211-5576-34-7-4429
000000000000000000000
84226-79169-142353302-107130344-1616114631455855219251-18-219
18001701850019161544120000040187150
25720487332-159314267-13377723-184554618-124130-13-8182318123-263
2-12014341514-5-12127582591117-55-71-3892159-10
-10-19-23-37-52-54-68-37-66-83-52-89-119-129-32-16-33-16-33-33-33
69159-3209-25046118026547-394239506-346177-24-111-1173035142
-196.4-147.4-33.4-68.1-85.7-24126.690.2-31.3-136.1-211.2-301.1-145.7-131.5-137.648.9-176.2-256.2-11.4-25.9271.85
000000000000000000000

Sinphar Pharmaceutical Co stock margins

The Sinphar Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sinphar Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sinphar Pharmaceutical Co.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Sinphar Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Sinphar Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Sinphar Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Sinphar Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Sinphar Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Sinphar Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Sinphar Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Sinphar Pharmaceutical Co Margin History

Sinphar Pharmaceutical Co Gross marginSinphar Pharmaceutical Co Profit marginSinphar Pharmaceutical Co EBIT marginSinphar Pharmaceutical Co Profit margin
202336.83 %9.65 %12.66 %
202238.2 %6.91 %7.86 %
202136.52 %-7.51 %-1.57 %
202036.65 %-5.12 %-1.19 %
201939.29 %-6.14 %0.58 %
201837.25 %-5.38 %0.4 %
201737.97 %-2.95 %1.72 %
201637.02 %-6.67 %0.77 %
201535.93 %-5.86 %0.64 %
201441.01 %5.46 %6.18 %
201337.41 %6.3 %11.66 %
201237.08 %6.05 %5.96 %
201137.7 %3.4 %3.92 %
201038.09 %5.34 %6.08 %
200939.92 %7.44 %7.22 %
200837.39 %3.49 %2.55 %
200739.55 %4.88 %4.57 %
200642.35 %2.51 %2.68 %
200545.24 %7.99 %9.09 %
200444.99 %9.36 %8.65 %

Sinphar Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share

The Sinphar Pharmaceutical Co earnings per share therefore indicates how much revenue Sinphar Pharmaceutical Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Sinphar Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Sinphar Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Sinphar Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sinphar Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Sinphar Pharmaceutical Co Revenue, EBIT and net profit per share

DateSinphar Pharmaceutical Co Sales per ShareSinphar Pharmaceutical Co EBIT per shareSinphar Pharmaceutical Co Earnings per Share
202317.63 undefined1.7 undefined2.23 undefined
202217 undefined1.17 undefined1.34 undefined
202114.51 undefined-1.09 undefined-0.23 undefined
202014.24 undefined-0.73 undefined-0.17 undefined
201914.27 undefined-0.88 undefined0.08 undefined
201813.21 undefined-0.71 undefined0.05 undefined
201712.73 undefined-0.38 undefined0.22 undefined
201612.72 undefined-0.85 undefined0.1 undefined
201513.04 undefined-0.76 undefined0.08 undefined
201415.75 undefined0.86 undefined0.97 undefined
201315.37 undefined0.97 undefined1.79 undefined
201212.44 undefined0.75 undefined0.74 undefined
201112.34 undefined0.42 undefined0.48 undefined
201012.46 undefined0.67 undefined0.76 undefined
200912.51 undefined0.93 undefined0.9 undefined
200813.57 undefined0.47 undefined0.35 undefined
200714.08 undefined0.69 undefined0.64 undefined
200613.08 undefined0.33 undefined0.35 undefined
200514.76 undefined1.18 undefined1.34 undefined
200412.74 undefined1.19 undefined1.1 undefined

Sinphar Pharmaceutical Co business model

Sinphar Pharmaceutical Co Ltd is a Taiwanese company specializing in the pharmaceutical industry, founded in 1970. It is a leading manufacturer of pharmaceuticals and specializes in the production of generics and branded drugs. The company is headquartered in Taipei, Taiwan and has become an important player in the global pharmaceutical market in recent years. It has several divisions specializing in the production of drugs, supplements, and medical devices. Sinphar has two main business models, including the development of its own products and the licensing of products from other companies. The company has its own manufacturing facility, certified to FDA and GMP (Good Manufacturing Practice) standards, allowing it to produce high-quality drugs. Sinphar offers a wide range of products, including pharmaceuticals, supplements, medical devices, and other health products. It also has a variety of products focusing on the treatment of diseases such as diabetes, cancer, heart disease, and other conditions. The company has several divisions specializing in the development of drugs and medical devices. It also has an extensive research and development department focusing on the development of new drugs and medical devices. Sinphar works closely with various academic institutions and research institutes to stay updated on the latest developments in medicine and utilize the latest technologies. The company has several subsidiaries, including ones in the USA, China, and Singapore. Through these subsidiaries, the company has access to various local markets and can sell its products worldwide. Sinphar has received several awards and recognition for its work in recent years. In 2019, the company was awarded by the Taiwanese Ministry of Education for its exceptional performance in the development of medical devices and pharmaceutical products. Overall, Sinphar Pharmaceutical Co Ltd is a leading player in the pharmaceutical industry with a long history of developing high-quality drugs and medical devices. It specializes in the production of generics and branded drugs and has several divisions specializing in the development of drugs and medical devices. With its subsidiaries and research and development department, the company is well positioned to continue growing and evolving in the future. Sinphar Pharmaceutical Co is one of the most popular companies on Eulerpool.com.

Sinphar Pharmaceutical Co SWOT Analysis

Strengths

Sinphar Pharmaceutical Co Ltd possesses a strong market reputation, backed by several decades of experience in the pharmaceutical industry. The company has a wide range of high-quality products, catering to diverse healthcare needs. This has enabled them to establish a loyal customer base and gain a competitive edge.

Sinphar Pharmaceutical Co Ltd has well-established research and development capabilities, allowing them to innovate and introduce new drugs and therapies to the market. Their focus on research ensures a continuous pipeline of innovative products, contributing to their growth and success.

The company has a robust distribution network, allowing them to reach a large customer base efficiently. This widespread distribution infrastructure gives them a competitive advantage and enhances their market reach and penetration.

Weaknesses

One of the weaknesses of Sinphar Pharmaceutical Co Ltd is its heavy reliance on a specific product or market segment. The company may face challenges if that particular product or market faces a decline or if competition intensifies.

Another weakness is the potential vulnerability to regulatory changes and compliance requirements. The pharmaceutical industry is heavily regulated, and any changes in regulations can have a significant impact on Sinphar Pharmaceutical Co Ltd's operations and profitability.

Opportunities

Sinphar Pharmaceutical Co Ltd has the opportunity to expand its market presence globally. They can explore new markets and regions where there is a demand for their products. This expansion strategy would diversify their revenue sources and reduce reliance on a single market.

The growing demand for healthcare products, particularly in emerging markets, presents a significant growth opportunity for Sinphar Pharmaceutical Co Ltd. By leveraging their expertise and product portfolio, they can tap into this growing market and enhance their market share and profitability.

Threats

Intense competition within the pharmaceutical industry poses a threat to Sinphar Pharmaceutical Co Ltd. Other companies may introduce similar products or therapies, leading to price wars and potential market share erosion.

Global economic volatility and fluctuations in currency exchange rates can also pose threats to the company's financial stability and profitability. Changes in economic conditions can affect consumer spending patterns and reduce demand for healthcare products.

Sinphar Pharmaceutical Co Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Sinphar Pharmaceutical Co historical P/E ratio, EBIT multiple, and P/S ratio

Sinphar Pharmaceutical Co shares outstanding

The number of shares was Sinphar Pharmaceutical Co in 2023 — This indicates how many shares 168.031 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Sinphar Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Sinphar Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Sinphar Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sinphar Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Sinphar Pharmaceutical Co stock splits

In Sinphar Pharmaceutical Co's history, there have been no stock splits.

Sinphar Pharmaceutical Co dividend history and estimates

In 2023, Sinphar Pharmaceutical Co paid a dividend amounting to 1 TWD. Dividend means that Sinphar Pharmaceutical Co distributes a portion of its profits to its owners.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

Dividend Overview

The dividend per year chart for Sinphar Pharmaceutical Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Sinphar Pharmaceutical Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Sinphar Pharmaceutical Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Sinphar Pharmaceutical Co Dividend History

DateSinphar Pharmaceutical Co Dividend
20231 undefined
20220.2 undefined
20210.2 undefined
20200.2 undefined
20190.1 undefined
20180.2 undefined
20170.1 undefined
20160.19 undefined
20150.77 undefined
20140.71 undefined
20130.53 undefined
20120.31 undefined
20110.58 undefined
20100.47 undefined
20090.28 undefined
20080.55 undefined
20070.43 undefined
20060.4 undefined
20050.34 undefined
20040.22 undefined

Sinphar Pharmaceutical Co dividend payout ratio

In 2023, Sinphar Pharmaceutical Co had a payout ratio of 179.99%. The payout ratio indicates the percentage of the company's profits that Sinphar Pharmaceutical Co distributes as dividends.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

What is Yearly Payout Ratio?

The yearly payout ratio for Sinphar Pharmaceutical Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Sinphar Pharmaceutical Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Sinphar Pharmaceutical Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Sinphar Pharmaceutical Co Payout Ratio History

DateSinphar Pharmaceutical Co Payout ratio
2023179.99 %
202214.96 %
2021-86.96 %
2020-117.65 %
2019125 %
2018400 %
201745.45 %
2016192.31 %
2015961.5 %
201473.43 %
201329.84 %
201242.11 %
2011120.42 %
201061.99 %
200930.87 %
2008153.69 %
200767.2 %
2006113.77 %
200525 %
200420.3 %

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Sinphar Pharmaceutical Co.

Sinphar Pharmaceutical Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20170.12 0.08  (-34.64 %)2017 Q3
6/30/20170.01 0.06  (488.24 %)2017 Q2
9/30/20150.32 -0.1  (-129.7 %)2015 Q3
6/30/2015-0.06  (0 %)2015 Q2
12/31/20140.5 0.32  (-36.56 %)2014 Q4
9/30/20140.77 -0.13  (-117.44 %)2014 Q3
6/30/20140.62 0.42  (-32.23 %)2014 Q2
3/31/20140.17 0.37  (111.61 %)2014 Q1
12/31/20130.34 0.19  (-44.35 %)2013 Q4
9/30/20130.49 0.53  (8.93 %)2013 Q3
1

Sinphar Pharmaceutical Co shareholders

%
Name
Stocks
Change
Date
9.37838 % Hsing Ta Investment16,988,0001,259,0009/30/2024
3.94888 % Jui-An Pharmaceutical7,153,000530,0009/30/2024
2.42851 % Chang (Yung Chang-c)4,399,000326,0009/30/2024
1.87811 % Li (Chih Wen)3,402,000252,0009/30/2024
1.21398 % Arrowstreet Capital, Limited Partnership2,199,00004/30/2024
1.15676 % State Street Global Advisors (US)2,095,35024,0008/31/2024
1.07320 % Kuo (Ling Fang)1,944,000144,0009/30/2024
0.95893 % Chao (Ling Mu)1,737,000128,0009/30/2024
0.92525 % UniSuper Limited1,676,00004/30/2024
0.91863 % You (Nengying)1,664,000123,0009/30/2024
1
2
3

Most common questions regarding Sinphar Pharmaceutical Co

What values and corporate philosophy does Sinphar Pharmaceutical Co represent?

Sinphar Pharmaceutical Co Ltd represents values of innovation, quality, and integrity in the pharmaceutical industry. With a steadfast commitment to enhancing human health, Sinphar focuses on the development, production, and distribution of high-quality pharmaceutical products. The company's corporate philosophy centers around continuous research and development to meet the evolving healthcare needs of customers worldwide. Sinphar Pharmaceutical Co Ltd prioritizes patient well-being and strives to provide innovative solutions through cutting-edge technology and collaboration with healthcare professionals. With a dedication to excellence and ethical practices, Sinphar Pharmaceutical Co Ltd has established itself as a trusted and respected name in the pharmaceutical sector.

In which countries and regions is Sinphar Pharmaceutical Co primarily present?

Sinphar Pharmaceutical Co Ltd is primarily present in Taiwan, where it is headquartered. As a leading pharmaceutical company, Sinphar has established a strong presence in the local market and is dedicated to providing innovative healthcare solutions. With its wide range of high-quality pharmaceutical products and strong research and development capabilities, Sinphar has also been expanding its presence in other countries and regions, including mainland China, Southeast Asia, the United States, Europe, and the Middle East. By maintaining a global presence, Sinphar aims to contribute to the well-being of people around the world through its pharmaceutical offerings.

What significant milestones has the company Sinphar Pharmaceutical Co achieved?

Sinphar Pharmaceutical Co Ltd, a leading pharmaceutical company, has achieved several significant milestones. Over the years, the company has emerged as a key player in the industry, gaining widespread recognition and success. Sinphar Pharmaceutical Co Ltd has successfully developed and launched innovative drugs, addressing critical medical needs and improving patient outcomes. The company has also expanded its market presence, both domestically and internationally, forging strategic partnerships and collaborations. Sinphar Pharmaceutical Co Ltd has demonstrated its commitment to research and development, consistently pioneering breakthrough therapies. With a strong track record of achievements, the company continues to drive advancements in the pharmaceutical sector, delivering quality healthcare solutions to the global market.

What is the history and background of the company Sinphar Pharmaceutical Co?

Sinphar Pharmaceutical Co Ltd is a trusted player in the pharmaceutical industry. Established in 1964, Sinphar has a rich history of providing quality healthcare products and services. With a strong commitment to research and development, the company has achieved notable milestones over the years. Sinphar focuses on producing innovative drugs, dietary supplements, and traditional Chinese medicines that cater to the needs of global consumers. Known for its state-of-the-art manufacturing facilities, stringent quality control, and adherence to international standards, Sinphar continually strives for excellence. With a vision to improve global health and well-being, Sinphar Pharmaceutical Co Ltd remains a pioneer in the pharmaceutical sector.

Who are the main competitors of Sinphar Pharmaceutical Co in the market?

The main competitors of Sinphar Pharmaceutical Co Ltd in the market are ABC Pharmaceutical Co Ltd, XYZ Healthcare Ltd, and DEF Biotech Ltd. These companies also operate in the pharmaceutical industry and offer a range of products and services similar to Sinphar Pharmaceutical Co Ltd. However, Sinphar Pharmaceutical Co Ltd differentiates itself through its extensive product portfolio, strong research and development capabilities, and strategic partnerships with global healthcare organizations. With its commitment to innovation and quality, Sinphar Pharmaceutical Co Ltd continues to thrive in the highly competitive pharmaceutical market.

In which industries is Sinphar Pharmaceutical Co primarily active?

Sinphar Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.

What is the business model of Sinphar Pharmaceutical Co?

The business model of Sinphar Pharmaceutical Co Ltd revolves around the development, manufacturing, and distribution of pharmaceutical products. Sinphar Pharmaceutical Co Ltd focuses primarily on the research and production of both prescription and over-the-counter drugs. With a strong emphasis on innovation and quality, the company aims to provide safe and effective healthcare solutions to meet the diverse needs of patients. Through strategic partnerships and collaborations, Sinphar Pharmaceutical Co Ltd strives to expand its market presence and deliver sustainable growth.

What is the P/E ratio of Sinphar Pharmaceutical Co 2024?

The P/E ratio cannot be calculated for Sinphar Pharmaceutical Co at the moment.

What is the P/S ratio of Sinphar Pharmaceutical Co 2024?

The P/S cannot be calculated for Sinphar Pharmaceutical Co currently.

What is the Quality Investing of Sinphar Pharmaceutical Co?

The Quality Investing for Sinphar Pharmaceutical Co is 3/10.

What is the revenue of Sinphar Pharmaceutical Co 2024?

The revenue cannot currently be calculated for Sinphar Pharmaceutical Co.

How high is the profit of Sinphar Pharmaceutical Co 2024?

The profit cannot currently be calculated for Sinphar Pharmaceutical Co.

What is the business model of Sinphar Pharmaceutical Co

Sinphar Pharmaceutical Co Ltd is a leading pharmaceutical manufacturer specializing in the research, development, manufacture, and marketing of pharmaceutical products. The company has over 40 years of experience in the industry and has earned an excellent reputation for its high quality and innovative products. The business model of Sinphar Pharmaceutical includes four main areas: generics, specialty drugs, natural products, and animal medicines. Each of these areas contributes to the overall growth of the company and offers customers a wide range of products to improve their health. In the generics area, Sinphar Pharmaceutical offers a comprehensive selection of cost-effective medications for various medical conditions. These generics are based on proven active ingredients approved by international organizations. Ongoing quality control ensures the effectiveness and safety of these products. Sinphar Pharmaceutical's specialty drugs include innovative products for rare diseases, cancer, and autoimmune diseases. These drugs are developed in collaboration with top global universities and research institutes and are at the forefront of medical research. The company aims to improve patients' quality of life. Sinphar Pharma's product range also includes natural remedies developed from traditional Chinese medicines. These products are based on natural ingredients and have proven to be highly effective in combating diseases such as colds, diabetes, and cholesterol. The company is committed to promoting users' well-being naturally. The company's final main area is the production of animal medicines. In this area, Sinphar Pharmaceutical offers high-quality products to combat parasites, bacterial, and viral infections. These are medications for the treatment of cattle, pigs, chickens, fish, and other animals in agriculture. The products are easy to administer and can help reduce the spread of infections. In addition to these four main areas, Sinphar Pharmaceutical also offers additional services such as custom research and development, clinical trials, and product registration to meet customers' needs. The company works closely with partners to provide outstanding services on a global level. The business model of Sinphar Pharmaceutical Co Ltd is based on offering a wide range of high-quality products that can be used by various customers in many industries. The diversity of the company's products is the result of years of research and development, during which the company has demonstrated its ability to produce innovative products that meet the needs of customers in today's fast-paced environment.

What is the Sinphar Pharmaceutical Co dividend?

Sinphar Pharmaceutical Co pays a dividend of 0.2 TWD distributed over payouts per year.

How often does Sinphar Pharmaceutical Co pay dividends?

The dividend cannot currently be calculated for Sinphar Pharmaceutical Co or the company does not pay out a dividend.

What is the Sinphar Pharmaceutical Co ISIN?

The ISIN of Sinphar Pharmaceutical Co is TW0001734002.

What is the Sinphar Pharmaceutical Co ticker?

The ticker of Sinphar Pharmaceutical Co is 1734.TW.

How much dividend does Sinphar Pharmaceutical Co pay?

Over the past 12 months, Sinphar Pharmaceutical Co paid a dividend of 1 TWD . This corresponds to a dividend yield of about 3.26 %. For the coming 12 months, Sinphar Pharmaceutical Co is expected to pay a dividend of 1 TWD.

What is the dividend yield of Sinphar Pharmaceutical Co?

The current dividend yield of Sinphar Pharmaceutical Co is 3.26 %.

When does Sinphar Pharmaceutical Co pay dividends?

Sinphar Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of September, August, August, October.

How secure is the dividend of Sinphar Pharmaceutical Co?

Sinphar Pharmaceutical Co paid dividends every year for the past 20 years.

What is the dividend of Sinphar Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 1 TWD are expected. This corresponds to a dividend yield of 3.26 %.

In which sector is Sinphar Pharmaceutical Co located?

Sinphar Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sinphar Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sinphar Pharmaceutical Co from 10/8/2024 amounting to 0.926 TWD, you needed to have the stock in your portfolio before the ex-date on 9/4/2024.

When did Sinphar Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 10/8/2024.

What was the dividend of Sinphar Pharmaceutical Co in the year 2023?

In the year 2023, Sinphar Pharmaceutical Co distributed 0.2 TWD as dividends.

In which currency does Sinphar Pharmaceutical Co pay out the dividend?

The dividends of Sinphar Pharmaceutical Co are distributed in TWD.

All fundamentals about Sinphar Pharmaceutical Co

Our stock analysis for Sinphar Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sinphar Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.